Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

22 trials with published results (18%)

Research Maturity

58 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.6%

8 terminated out of 122 trials

Success Rate

87.9%

+1.4% vs benchmark

Late-Stage Pipeline

22%

27 trials in Phase 3/4

Results Transparency

38%

22 of 58 completed with results

Key Signals

22 with results88% success

Data Visualizations

Phase Distribution

82Total
Not Applicable (38)
Early P 1 (1)
P 1 (4)
P 2 (12)
P 3 (16)
P 4 (11)

Trial Status

Completed58
Recruiting21
Unknown19
Terminated8
Active Not Recruiting7
Not Yet Recruiting6

Trial Success Rate

87.9%

Benchmark: 86.5%

Based on 58 completed trials

Clinical Trials (122)

Showing 20 of 20 trials
NCT07148414Phase 2Recruiting

A Study of SPY072 in Rheumatic Disease

NCT07414823Not ApplicableActive Not RecruitingPrimary

Walking Football for Axial Spondyloarthritis

NCT06888193Phase 1Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT07290036Phase 1Recruiting

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT04436640Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT06844643RecruitingPrimary

The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study

NCT06526377Phase 2Not Yet RecruitingPrimary

Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis

NCT05785611Phase 3Active Not RecruitingPrimary

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT03420404Not ApplicableActive Not RecruitingPrimary

Clinical Trial of TCM Collaborative Care Model in Axial Spondyloarthritis

NCT06337513Not ApplicableEnrolling By InvitationPrimary

Spondyloarthritis Inception Cohort of Southern Denmark

NCT02374749Not ApplicableCompletedPrimary

COMorbidities and EDucation in SPondyloArthritis Study

NCT05006690Not ApplicableCompletedPrimary

Telerehabilitation and Face-to-Face Clinical Pilates-Based Exercise in Individuals With Axial Spondyloarthritis

NCT06583980Not ApplicableRecruiting

INSELMA - a Randomised Controlled Trial

NCT04115098Phase 2TerminatedPrimary

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

NCT06072859Not ApplicableCompletedPrimary

The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)

NCT06727266CompletedPrimary

Ultrasonographic Evaluation of the Shoulder Joint in Patients With Axial Spondyloarthritis

NCT06967077Not ApplicableNot Yet RecruitingPrimary

Exploring the Feasibility and Acceptability of Virtual Reality Exercise for Pain Management, Fear of Movement, Mobility, and Proprioception Deficit in Axial Spondyloarthritis Patients During Flares: Twics Design

NCT06968247Not ApplicableNot Yet RecruitingPrimary

Assessing the Feasibility of the Patient-Reported Outcomes Based Model for Community Care of Patients With Axial Spondyloarthritis Via a Type 1 Pilot Hybrid Effectiveness-Implementation Trial Using the RE-AIM Framework

NCT05812157Not ApplicableRecruitingPrimary

Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

Scroll to load more

Research Network

Activity Timeline